Abstract
Prostate cancer is predicted to be the most common cancer diagnosed in American men in 2006 with an estimated 230,000 new cases in the United States alone [1]. It is likely to result in over 27,000 deaths in 2006, and the average male will have a one in six chance of developing this malady in his lifetime [1]. These statistics illustrate the need to have screening and treatment systems in place that possess both a high degree of sensitivity as well as proven effectiveness. With the recent strides made in the field of molecular and cellular biology, it is now possible to analyze and tailor treatments to an individuals tumor. As the methods of analysis become more refined, researchers are better able to sift through the vast amounts of data and hone in on promising new targets. Molecular prognostic markers are already beginning to appear as a result of modern genomic analysis, and more are on the way. These markers are appearing in a variety of pathways including signal transduction, apoptosis, cell cycle regulation, angiogenesis, and cell adhesion. The emergence of viable prognostic markers indicative of specific tumor types holds the potential of greatly improving cancer screening methods as well as overall patient survival.
Keywords: Prostate cancer, biomarkers, prognosis, treatment
Current Cancer Therapy Reviews
Title: Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Volume: 3 Issue: 1
Author(s): Gregory Saia, Min Zhang, Vincent Depalo, Tim Lautenschlager and Arnab Chakravarti
Affiliation:
Keywords: Prostate cancer, biomarkers, prognosis, treatment
Abstract: Prostate cancer is predicted to be the most common cancer diagnosed in American men in 2006 with an estimated 230,000 new cases in the United States alone [1]. It is likely to result in over 27,000 deaths in 2006, and the average male will have a one in six chance of developing this malady in his lifetime [1]. These statistics illustrate the need to have screening and treatment systems in place that possess both a high degree of sensitivity as well as proven effectiveness. With the recent strides made in the field of molecular and cellular biology, it is now possible to analyze and tailor treatments to an individuals tumor. As the methods of analysis become more refined, researchers are better able to sift through the vast amounts of data and hone in on promising new targets. Molecular prognostic markers are already beginning to appear as a result of modern genomic analysis, and more are on the way. These markers are appearing in a variety of pathways including signal transduction, apoptosis, cell cycle regulation, angiogenesis, and cell adhesion. The emergence of viable prognostic markers indicative of specific tumor types holds the potential of greatly improving cancer screening methods as well as overall patient survival.
Export Options
About this article
Cite this article as:
Saia Gregory, Zhang Min, Depalo Vincent, Lautenschlager Tim and Chakravarti Arnab, Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy, Current Cancer Therapy Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339407780126647
DOI https://dx.doi.org/10.2174/157339407780126647 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria
Current Drug Targets DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview
Current Drug Targets Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Drug Targets Prostate Cancer Gene Expression Marker 1 (PCGEM1): A Patented Prostate- Specific Non-Coding Gene and Regulator of Prostate Cancer Progression
Recent Patents on DNA & Gene Sequences The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Recent Developments on Thiourea Based Anticancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs and Diabetes Mellitus Type 1
Current Diabetes Reviews COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews The Pharmacology of Cyclic Nucleotide-Gated Channels: Emerging from the Darkness
Current Pharmaceutical Design Breakthrough Pain
Current Drug Therapy ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal Atranorin – An Interesting Lichen Secondary Metabolite
Mini-Reviews in Medicinal Chemistry Recent Advancement in Nonsteroidal Aromatase Inhibitors for Treatment of Estrogen-Dependent Breast Cancer
Current Medicinal Chemistry Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design Experimental Drugs for Neuropathic Pain
Current Neuropharmacology 3-Carboranyl Thymidine Analogues (3CTAs) and Other Boronated Nucleosides for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry